Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy + CAPOX + sintilimab with or without FMT in locally advanced rectal cancer
ChiCTR2600117587Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in rectal adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Complete Response Rate (CR). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600117587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117587.